Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

BSEM US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

BSEM US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

BioStem Technologies, Inc.(BSEM US)

$1.14-0.1712.69%(Market Open · 16:41:04 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

BioStem Technologies, Inc.(BSEM US)

$1.14-0.1712.69%(Market Open · 16:41:04 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Financials & Metrics

FinancialsChartingShort InterestEmployees

BioStem Technologies, Inc. — Company Profile

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.

Sector
Materials
Industry
Paper & Forest Products
Exchange
UQ
CEO
Jason Matuszewski
Headquarters
Fort Lauderdale, FL, US
IPO Date
Mar 17, 2015
Employees
73
Website
biostemtechnologies.com

Key Metrics

Price
$2.73
Market Cap
$46.37M
Revenue (TTM)
$6.14M
Net Income (TTM)
$-8819705.00
EPS (TTM)
-0.52
P/E (TTM)
-2.33
P/B (TTM)
1.45
Dividend Yield
0.00%
ROE (TTM)
-16.81%
ROA (TTM)
-13.15%
Operating Margin
-1.45%
Beta
1.75

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.

Website
biostemtechnologies.com
Location
Fort Lauderdale, FL, US
Phone954 380 8342
Employees73
CEOJason Matuszewski
Sector
Materials
Industry
Paper & Forest Products
IPO DateMar 17, 2015

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(76)

Expand
  • 10-QQ3ended 30 Sept 202612 Nov
  • 8-KResults of Operations and Financial Condition12 Nov
  • Form 4FORTUNATO MICHAEL A10 Nov
  • SC 13GBioStem Technologies, Inc.10 Nov
  • SC 13GBioStem Technologies, Inc.10 Nov
  • SC 13GBioStem Technologies, Inc.5 Nov
  • Form 4HASSETT BARRY3 Nov
  • SEC STAFF LETTERSEC STAFF LETTER16 Oct
  • 424B3PROSPECTUS13 Oct
  • EFFECTNotice of effectiveness13 Oct
  • Form 4SMITH-VAN VURST ANDREW9 Oct
  • Form 4Matuszewski Jason9 Oct
  • DRule 506(b) provides a "safer harbor" for a private offering9 Oct
  • S-8REGISTRATION STATEMENT6 Oct
  • S-1REGISTRATION STATEMENT2 Oct
  • 8-KEntry into a Material Definitive Agreement30 Sep
  • EFFECTNotice of effectiveness30 Sep
  • 424B3PROSPECTUS29 Sep
  • CORRESPFiling review correspondence25 Sep
  • DRule 506(b) provides a "safer harbor" for a private offering21 Sep

News

  • BioStem Technologies, Inc. (BSEM) Q3 2026 Earnings Call Transcript12 Nov
  • BioStem Technologies, Inc. (BSEM) Reports Q3 Loss, Beats Revenue Estimates12 Nov
  • BioStem Technologies Reports Third Quarter 2026 Financial Results; Grows Hospital Revenue for Second Consecutive Quarter as Customers Expand Use of Portfolio12 Nov
  • BioStem Technologies to Host Third Quarter 2026 Financial Results Conference Call on November 12, 202629 Oct
  • BioStem Technologies' CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options8 Oct
  • BioStem Technologies' CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options8 Oct
  • Century Therapeutics (NASDAQ:IPSC) and BioStem Technologies (OTCMKTS:BSEM) Financial Analysis4 Oct
  • BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio1 Oct
  • BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio1 Oct
  • BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules30 Sep
  • BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules30 Sep
  • Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform21 Sep
  • BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility18 Sep
  • BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility18 Sep
  • BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier4 Sep
  • BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier4 Sep
  • BioStem Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference3 Sep
  • BioStem Technologies Eyes Surgical Growth, Manufacturing Shift After BioTissue Deal21 Aug
  • Comparing BioStem Technologies (OTCMKTS:BSEM) and Enlivex Therapeutics (NASDAQ:ENLV)21 Aug
  • BioStem Technologies to Present at the Sidoti MicroCap Conference14 Aug

Mentions in Filings

  • ?
    September 25, 2026 Jason Matuszewski Chief Executive Officer <strong>BioStem Technologies, Inc.</strong> 2836 Center Port Circle Pompano Beach, FL 33064 Re: BioStem Technologies, Inc. Registration Statement on Form S-1 Filed September 18, 2026 File No. 333-299025 Dear Jason Matuszewski: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We …
    BioStem Technologies, Inc.·TEXT-EXTRACT - UPLOAD - Filing review upload·25 Sep·25 Sep
  • ?
    September 25, 2026 Jason Matuszewski Chief Executive Officer <strong>BioStem Technologies, Inc.</strong> 2836 Center Port Circle Pompano Beach, FL 33064 Re: BioStem Technologies, Inc. Registration Statement on Form S-1 Filed September 18, 2026 File No. 333-299025 Dear Jason Matuszewski: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remin …
    BioStem Technologies, Inc.·LETTER - UPLOAD - Filing review upload·25 Sep·25 Sep
  • ?
    July 22, 2026 Jason Matuszewski Chief Executive Officer <strong>BioStem Technologies, Inc.</strong> 2836 Center Port Circle Pompano Beach, FL 33064 Re: BioStem Technologies, Inc. Registration Statement on Form 10 Filed July 10, 2026 File No. 000-56861 Dear Jason Matuszewski: We have reviewed your filing and have the following comments. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible …
    BioStem Technologies, Inc.·LETTER - UPLOAD - Filing review upload·22 Jul·22 Jul
  • ?
    July 22, 2026 Jason Matuszewski Chief Executive Officer <strong>BioStem Technologies, Inc.</strong> 2836 Center Port Circle Pompano Beach, FL 33064 Re: BioStem Technologies, Inc. Registration Statement on Form 10 Filed July 10, 2026 File No. 000-56861 Dear Jason Matuszewski: We have reviewed your filing and have the following comments. Please respond to this letter within ten business days by providing the requested information or advise us as soon as pos …
    BioStem Technologies, Inc.·TEXT-EXTRACT - UPLOAD - Filing review upload·22 Jul·22 Jul
  • ?
    June 15, 2026 Jason Matuszewski Chief Executive Officer <strong>BioStem Technologies, Inc.</strong> 2836 Center Port Circle Pompano Beach, FL 33064 Re: BioStem Technologies, Inc. Amendment No. 1 to Draft Registration Statement on Form 10 Submitted May 28, 2026 CIK No. 0001658678 Dear Jason Matuszewski: We have reviewed your amended draft registration statement and have the following comments. Please respond to this letter by providing the requested information …
    BioStem Technologies, Inc.·LETTER - UPLOAD - Filing review upload·15 Jun·15 Jun
  • ?
    June 15, 2026 Jason Matuszewski Chief Executive Officer <strong>BioStem Technologies, Inc.</strong> 2836 Center Port Circle Pompano Beach, FL 33064 Re: BioStem Technologies, Inc. Amendment No. 1 to Draft Registration Statement on Form 10 Submitted May 28, 2026 CIK No. 0001658678 Dear Jason Matuszewski: We have reviewed your amended draft registration statement and have the following comments. Please respond to this letter by providing the requested inform …
    BioStem Technologies, Inc.·TEXT-EXTRACT - UPLOAD - Filing review upload·15 Jun·15 Jun

Key Stats

Trading

Px/Chg 1D$2.73 / -11.07%
Prev Close$3.71
% of 52Wk H47.62%
Avg Volume60.43K
Beta1.75
Mkt Cap46.37M
FD Mkt Cap67.94M

Float

Shrs Out/Float16.98M / 12.54M
Short Float0.03%
Days to Cover4.43
Stock Repurchased$0.00

Current Valuation

EV35.94M
EV/EBITDA-2.55
EV/Sales-1.90
P/B1.45
P/S-2.45
FCF Yield5.16%
ROE-16.81%
ROA-13.15%
Current Ratio4.12

Estimates

P/E-2.33
Est P/E0.00
Est EPS-0.28
Est PEG0.00

Valuation

Metric5Yr AvgMar '23Mar '24Mar '25Mar '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-6.31-5.64-19.364.69-6.11-5.14
Price / Sales4.545.819.840.50-0.817.39
Price / Book Value-25.02-9.79-122.153.661.761.42
Price / Free Cash Flow-2.11-18.95-45.566.2128.7618.97
ENTERPRISE VALUE METRICS
Enterprise Value84.444.5168.7131.142.534.9
Enterprise Value / Sales4.446.4710.110.43-0.505.69
Enterprise Value / EBITDA-6.98-6.82-22.344.16-5.69-4.19
Enterprise Value / EBIT-6.73-6.58-21.684.20-5.66-3.93

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue81.9%4.36.916.7301.847.5
Gross Income98.2%2.96.015.4287.944.2
EBITDA-6%-0.6-6.5-7.631.5-0.5
EBIT-6.1%-0.9-6.8-7.831.2-0.7
Net Income46.1%-1.4-7.1-8.531.9-6.6
EPS (Diluted)34.3%-0.12-0.62-0.621.47-0.39
BALANCE SHEET
Cash & ST Inv205.3%0.30.80.222.829.5
Total Assets108%2.73.514.6140.550.0
Total Liabilities6.5%8.57.415.999.710.9
Total Shareholder Equity—-6.0-4.1-1.340.939.1
CASH FLOW
Net Operating Cash Flow—-0.1-1.6-3.524.59.9
Cap Ex197.4%-0.0-0.5-0.1-0.4-3.4
Free Cash Flow—-0.2-2.1-3.624.16.6

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)1.13
Basic Shares16.98
Market Cap19.2
Diluted Shares17.33
Fully Diluted Shares Outstanding17.33
Fully Diluted Market Cap19.6
+Consolidated Debt1.2
−In-the-Money Convertible Debt—
+Capital Leases0.0
+Operating Leases—
−Cash & Equivalents-7.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value13.5

Related companies

Amgen Inc

AMGN US

Gilead Sciences, Inc.

GILD US

Intuitive Surgical Inc

ISRG US

Moderna, Inc.

MRNA US

Argenx Se

ARGX US

Edwards Lifesciences Corporation

EW US

Revolution Medicines, Inc.

RVMD US

Biogen Inc.

BIIB US

BioNTech SE

BNTX US

STERIS plc

STE US

Nordson Corp

NDSN US

Tyson Foods, Inc.

TSN US

BioStem Technologies, Inc. — Company Profile

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.

Sector
Materials
Industry
Paper & Forest Products
Exchange
UQ
CEO
Jason Matuszewski
Headquarters
Fort Lauderdale, FL, US
IPO Date
Mar 17, 2015
Employees
73
Website
biostemtechnologies.com

Key Metrics

Price
$2.73
Market Cap
$46.37M
Revenue (TTM)
$6.14M
Net Income (TTM)
$-8819705.00
EPS (TTM)
-0.52
P/E (TTM)
-2.33
P/B (TTM)
1.45
Dividend Yield
0.00%
ROE (TTM)
-16.81%
ROA (TTM)
-13.15%
Operating Margin
-1.45%
Beta
1.75

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.

Website
biostemtechnologies.com
Location
Fort Lauderdale, FL, US
Phone954 380 8342
Employees73
CEOJason Matuszewski
Sector
Materials
Industry
Paper & Forest Products
IPO DateMar 17, 2015

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(76)

Expand
  • 10-QQ3ended 30 Sept 202612 Nov
  • 8-KResults of Operations and Financial Condition12 Nov
  • Form 4FORTUNATO MICHAEL A10 Nov
  • SC 13GBioStem Technologies, Inc.10 Nov
  • SC 13GBioStem Technologies, Inc.10 Nov
  • SC 13GBioStem Technologies, Inc.5 Nov
  • Form 4HASSETT BARRY3 Nov
  • SEC STAFF LETTERSEC STAFF LETTER16 Oct
  • 424B3PROSPECTUS13 Oct
  • EFFECTNotice of effectiveness13 Oct
  • Form 4SMITH-VAN VURST ANDREW9 Oct
  • Form 4Matuszewski Jason9 Oct
  • DRule 506(b) provides a "safer harbor" for a private offering9 Oct
  • S-8REGISTRATION STATEMENT6 Oct
  • S-1REGISTRATION STATEMENT2 Oct
  • 8-KEntry into a Material Definitive Agreement30 Sep
  • EFFECTNotice of effectiveness30 Sep
  • 424B3PROSPECTUS29 Sep
  • CORRESPFiling review correspondence25 Sep
  • DRule 506(b) provides a "safer harbor" for a private offering21 Sep

News

  • BioStem Technologies, Inc. (BSEM) Q3 2026 Earnings Call Transcript12 Nov
  • BioStem Technologies, Inc. (BSEM) Reports Q3 Loss, Beats Revenue Estimates12 Nov
  • BioStem Technologies Reports Third Quarter 2026 Financial Results; Grows Hospital Revenue for Second Consecutive Quarter as Customers Expand Use of Portfolio12 Nov
  • BioStem Technologies to Host Third Quarter 2026 Financial Results Conference Call on November 12, 202629 Oct
  • BioStem Technologies' CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options8 Oct
  • BioStem Technologies' CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options8 Oct
  • Century Therapeutics (NASDAQ:IPSC) and BioStem Technologies (OTCMKTS:BSEM) Financial Analysis4 Oct
  • BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio1 Oct
  • BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio1 Oct
  • BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules30 Sep
  • BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules30 Sep
  • Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform21 Sep
  • BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility18 Sep
  • BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility18 Sep
  • BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier4 Sep
  • BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier4 Sep
  • BioStem Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference3 Sep
  • BioStem Technologies Eyes Surgical Growth, Manufacturing Shift After BioTissue Deal21 Aug
  • Comparing BioStem Technologies (OTCMKTS:BSEM) and Enlivex Therapeutics (NASDAQ:ENLV)21 Aug
  • BioStem Technologies to Present at the Sidoti MicroCap Conference14 Aug

Mentions in Filings

  • ?
    September 25, 2026 Jason Matuszewski Chief Executive Officer <strong>BioStem Technologies, Inc.</strong> 2836 Center Port Circle Pompano Beach, FL 33064 Re: BioStem Technologies, Inc. Registration Statement on Form S-1 Filed September 18, 2026 File No. 333-299025 Dear Jason Matuszewski: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We …
    BioStem Technologies, Inc.·TEXT-EXTRACT - UPLOAD - Filing review upload·25 Sep·25 Sep
  • ?
    September 25, 2026 Jason Matuszewski Chief Executive Officer <strong>BioStem Technologies, Inc.</strong> 2836 Center Port Circle Pompano Beach, FL 33064 Re: BioStem Technologies, Inc. Registration Statement on Form S-1 Filed September 18, 2026 File No. 333-299025 Dear Jason Matuszewski: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remin …
    BioStem Technologies, Inc.·LETTER - UPLOAD - Filing review upload·25 Sep·25 Sep
  • ?
    July 22, 2026 Jason Matuszewski Chief Executive Officer <strong>BioStem Technologies, Inc.</strong> 2836 Center Port Circle Pompano Beach, FL 33064 Re: BioStem Technologies, Inc. Registration Statement on Form 10 Filed July 10, 2026 File No. 000-56861 Dear Jason Matuszewski: We have reviewed your filing and have the following comments. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible …
    BioStem Technologies, Inc.·LETTER - UPLOAD - Filing review upload·22 Jul·22 Jul
  • ?
    July 22, 2026 Jason Matuszewski Chief Executive Officer <strong>BioStem Technologies, Inc.</strong> 2836 Center Port Circle Pompano Beach, FL 33064 Re: BioStem Technologies, Inc. Registration Statement on Form 10 Filed July 10, 2026 File No. 000-56861 Dear Jason Matuszewski: We have reviewed your filing and have the following comments. Please respond to this letter within ten business days by providing the requested information or advise us as soon as pos …
    BioStem Technologies, Inc.·TEXT-EXTRACT - UPLOAD - Filing review upload·22 Jul·22 Jul
  • ?
    June 15, 2026 Jason Matuszewski Chief Executive Officer <strong>BioStem Technologies, Inc.</strong> 2836 Center Port Circle Pompano Beach, FL 33064 Re: BioStem Technologies, Inc. Amendment No. 1 to Draft Registration Statement on Form 10 Submitted May 28, 2026 CIK No. 0001658678 Dear Jason Matuszewski: We have reviewed your amended draft registration statement and have the following comments. Please respond to this letter by providing the requested information …
    BioStem Technologies, Inc.·LETTER - UPLOAD - Filing review upload·15 Jun·15 Jun
  • ?
    June 15, 2026 Jason Matuszewski Chief Executive Officer <strong>BioStem Technologies, Inc.</strong> 2836 Center Port Circle Pompano Beach, FL 33064 Re: BioStem Technologies, Inc. Amendment No. 1 to Draft Registration Statement on Form 10 Submitted May 28, 2026 CIK No. 0001658678 Dear Jason Matuszewski: We have reviewed your amended draft registration statement and have the following comments. Please respond to this letter by providing the requested inform …
    BioStem Technologies, Inc.·TEXT-EXTRACT - UPLOAD - Filing review upload·15 Jun·15 Jun

Key Stats

Trading

Px/Chg 1D$2.73 / -11.07%
Prev Close$3.71
% of 52Wk H47.62%
Avg Volume60.43K
Beta1.75
Mkt Cap46.37M
FD Mkt Cap67.94M

Float

Shrs Out/Float16.98M / 12.54M
Short Float0.03%
Days to Cover4.43
Stock Repurchased$0.00

Current Valuation

EV35.94M
EV/EBITDA-2.55
EV/Sales-1.90
P/B1.45
P/S-2.45
FCF Yield5.16%
ROE-16.81%
ROA-13.15%
Current Ratio4.12

Estimates

P/E-2.33
Est P/E0.00
Est EPS-0.28
Est PEG0.00

Valuation

Metric5Yr AvgMar '23Mar '24Mar '25Mar '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-6.31-5.64-19.364.69-6.11-5.14
Price / Sales4.545.819.840.50-0.817.39
Price / Book Value-25.02-9.79-122.153.661.761.42
Price / Free Cash Flow-2.11-18.95-45.566.2128.7618.97
ENTERPRISE VALUE METRICS
Enterprise Value84.444.5168.7131.142.534.9
Enterprise Value / Sales4.446.4710.110.43-0.505.69
Enterprise Value / EBITDA-6.98-6.82-22.344.16-5.69-4.19
Enterprise Value / EBIT-6.73-6.58-21.684.20-5.66-3.93

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue81.9%4.36.916.7301.847.5
Gross Income98.2%2.96.015.4287.944.2
EBITDA-6%-0.6-6.5-7.631.5-0.5
EBIT-6.1%-0.9-6.8-7.831.2-0.7
Net Income46.1%-1.4-7.1-8.531.9-6.6
EPS (Diluted)34.3%-0.12-0.62-0.621.47-0.39
BALANCE SHEET
Cash & ST Inv205.3%0.30.80.222.829.5
Total Assets108%2.73.514.6140.550.0
Total Liabilities6.5%8.57.415.999.710.9
Total Shareholder Equity—-6.0-4.1-1.340.939.1
CASH FLOW
Net Operating Cash Flow—-0.1-1.6-3.524.59.9
Cap Ex197.4%-0.0-0.5-0.1-0.4-3.4
Free Cash Flow—-0.2-2.1-3.624.16.6

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)1.13
Basic Shares16.98
Market Cap19.2
Diluted Shares17.33
Fully Diluted Shares Outstanding17.33
Fully Diluted Market Cap19.6
+Consolidated Debt1.2
−In-the-Money Convertible Debt—
+Capital Leases0.0
+Operating Leases—
−Cash & Equivalents-7.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value13.5

Related companies

Amgen Inc

AMGN US

Gilead Sciences, Inc.

GILD US

Intuitive Surgical Inc

ISRG US

Moderna, Inc.

MRNA US

Argenx Se

ARGX US

Edwards Lifesciences Corporation

EW US

Revolution Medicines, Inc.

RVMD US

Biogen Inc.

BIIB US

BioNTech SE

BNTX US

STERIS plc

STE US

Nordson Corp

NDSN US

Tyson Foods, Inc.

TSN US